Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Novel method identifies undiagnosed drug-induced liver injury in cancer patients

27 Jul 2020

Researchers have recently developed a reliable and simple method to identify undiagnosed drug-induced liver injury (DILI) among cancer patients, reporting an annual incidence of 0.69 percent of chemotherapy-related liver injury among those admitted to an oncology department.

To establish such method and to assess current clinical approach to elevated laboratory liver test results, the researchers identified 289 patients admitted to an oncology department who had systemic chemotherapy episodes for cancer treatment from 1 January 2017 to 31 December 2017.

Hy’s law was applied to laboratory liver test results, with aid of healthcare information system, to identify potential hepatocellular DILI cases. The researchers then performed a medical record review among identified patients to exclude liver dysfunction of alternative causes. Moreover, the current clinical approach to elevated laboratory liver tests was assessed through medical record review.

One hundred twenty-three of 289 patients who were treated with systemic chemotherapies were found to have elevated laboratory liver tests. Of the identified patients, eight were suspected as potential Hy’s law cases.

Two patients were found to have chemotherapy-associated liver injury due to 5-fluorouracil, leucovorin, irinotecan, and S-1 plus paclitaxel separately after medical review. Seven (87.5 percent) of eight potential Hy’s law cases were prescribed with at least two kinds of liver protectants and remained treated with traditional Chinese medicine for decoction.

In another study that also developed a highly sensitive model to identify DILI patients at increased risk of acute liver failure (ALF), the authors concluded that Hy’s Law identified patients with DILI at high risk for ALF with low sensitivity but high specificity. [Clin Gastroenterol Hepatol 2015;13:2360-2368]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.